Jefferies Reiterates Buy Rating and $109 PT on Ultragenyx (RARE) Following 'Uneventful' 4Q16 Results
Jefferies analyst Gena Wang reiterates Buy rating and $109 price target on Ultragenyx Pharmaceuticals (NASDAQ: RARE), noting clinical progress across ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)